.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC10_Secukinumab.Secukinumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC10_Secukinumab.Secukinumab| name: | Secukinumab |
| ATC code: | L04AC10 | route: | subcutaneous |
| n-compartments | 2 |
Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of several autoimmune diseases. It is primarily used for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Secukinumab is an approved drug and is in regular clinical use.
Pharmacokinetics of secukinumab in adults with moderate to severe plaque psoriasis after subcutaneous administration.
Yao, F, et al., & Hu, W (2024). A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx. Drug design, development and therapy 18 3891–3901. DOI:10.2147/DDDT.S470619 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39224901
Bruin, G, et al., & Sander, O (2017). Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis. Journal of clinical pharmacology 57(7) 876–885. DOI:10.1002/jcph.876 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28273356
Dumortier, T, et al., & Marathe, A (2025). Model-Informed Drug Development-Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial Spondyloarthritis. Clinical pharmacology and therapeutics None –. DOI:10.1002/cpt.3716 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40454543